JP7434299B2 - インスリンペプチドおよびｅｇｆ（ａ）ペプチドを含む二官能性化合物 - Google Patents

インスリンペプチドおよびｅｇｆ（ａ）ペプチドを含む二官能性化合物 Download PDF

Info

Publication number
JP7434299B2
JP7434299B2 JP2021518432A JP2021518432A JP7434299B2 JP 7434299 B2 JP7434299 B2 JP 7434299B2 JP 2021518432 A JP2021518432 A JP 2021518432A JP 2021518432 A JP2021518432 A JP 2021518432A JP 7434299 B2 JP7434299 B2 JP 7434299B2
Authority
JP
Japan
Prior art keywords
insulin
egf
fusion protein
gaqp
gglu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021518432A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022504153A (ja
JP2022504153A5 (https=
Inventor
マルティン・ヴェルナー・ボルクセニウス・ミュンツェル
スサンネ・ホストロプ
グロ・クリットガード・ポールセン
マティアス・ノーマン
トマス・ボーグラム・ケルスン
クラウディア・ウルリク・ヒョリンハード
ペーター・マセン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of JP2022504153A publication Critical patent/JP2022504153A/ja
Publication of JP2022504153A5 publication Critical patent/JP2022504153A5/ja
Application granted granted Critical
Publication of JP7434299B2 publication Critical patent/JP7434299B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2021518432A 2018-10-05 2019-10-04 インスリンペプチドおよびｅｇｆ（ａ）ペプチドを含む二官能性化合物 Active JP7434299B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18198892.4 2018-10-05
EP18198892 2018-10-05
PCT/EP2019/076889 WO2020070276A1 (en) 2018-10-05 2019-10-04 Bifunctional compounds comprising insulin peptides and egf(a) peptides

Publications (3)

Publication Number Publication Date
JP2022504153A JP2022504153A (ja) 2022-01-13
JP2022504153A5 JP2022504153A5 (https=) 2022-10-12
JP7434299B2 true JP7434299B2 (ja) 2024-02-20

Family

ID=64017248

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021518432A Active JP7434299B2 (ja) 2018-10-05 2019-10-04 インスリンペプチドおよびｅｇｆ（ａ）ペプチドを含む二官能性化合物

Country Status (8)

Country Link
US (1) US11649269B2 (https=)
EP (1) EP3861017A1 (https=)
JP (1) JP7434299B2 (https=)
CN (1) CN112789289A (https=)
AR (1) AR116605A1 (https=)
MA (1) MA53809A (https=)
TW (1) TW202028229A (https=)
WO (1) WO2020070276A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018107117A1 (en) 2016-12-09 2018-06-14 Akston Biosciences Corporation Insulin-fc fusions and methods of use
KR20210029210A (ko) 2018-06-29 2021-03-15 악스톤 바이오사이언시스 코퍼레이션 초장기 작용 인슐린-fc 융합 단백질 및 사용 방법
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
KR20250142943A (ko) 2019-12-19 2025-09-30 악스톤 바이오사이언시스 코퍼레이션 초-장기 작용 인슐린-fc 융합 단백질 및 사용 방법
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
LT3972987T (lt) 2020-04-10 2023-09-25 Akston Biosciences Corporation Antigenui specifinė imunoterapija, skirta sulietiems covid-19 baltymams ir naudojimo būdai
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
CN114729060B (zh) 2020-09-30 2022-11-25 北京质肽生物医药科技有限公司 多肽缀合物和使用方法
EP4373861A4 (en) 2021-07-23 2025-08-20 Akston Biosciences Corp INSULIN-FC FUSION PROTEINS AND METHODS OF USE FOR TREATING CANCER
EP4323413A4 (en) 2022-03-30 2025-10-15 Beijing Ql Biopharmaceutical Co Ltd LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF
CN115947822B (zh) * 2022-07-04 2023-08-18 北京惠之衡生物科技有限公司 一种长效酰化胰岛素衍生物及其药物组合物和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009022006A1 (en) 2007-08-15 2009-02-19 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
WO2011117401A1 (en) 2010-03-25 2011-09-29 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. Use of pcsk9 as a vaccine for lowering cholesterol
WO2017121850A1 (en) 2016-01-13 2017-07-20 Novo Nordisk A/S Egf(a) analogues with fatty acid substituents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
MX2010011499A (es) 2008-04-23 2010-11-12 Amgen Inc Variantes de proproteina neutralizante de convertasa subtilisina kexina de tipo 9 (pcsk9) y sus usos.
WO2012177741A1 (en) 2011-06-20 2012-12-27 Genentech, Inc. Pcsk9-binding polypeptides and methods of use
CA2935285A1 (en) 2014-02-21 2015-08-27 Medimmune, Llc Anti-pcsk9-glp-1 fusions and methods for use
CN104558199B (zh) 2014-09-05 2018-07-06 成都康弘生物科技有限公司 一种治疗高胆固醇血症的融合蛋白制备及其用途
WO2016164762A1 (en) 2015-04-08 2016-10-13 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same
ES2908373T3 (es) 2015-08-25 2022-04-28 Novo Nordisk As Nuevos derivados de insulina y los usos médicos de los mismos

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009022006A1 (en) 2007-08-15 2009-02-19 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
WO2011117401A1 (en) 2010-03-25 2011-09-29 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. Use of pcsk9 as a vaccine for lowering cholesterol
WO2017121850A1 (en) 2016-01-13 2017-07-20 Novo Nordisk A/S Egf(a) analogues with fatty acid substituents

Also Published As

Publication number Publication date
JP2022504153A (ja) 2022-01-13
TW202028229A (zh) 2020-08-01
US11649269B2 (en) 2023-05-16
WO2020070276A1 (en) 2020-04-09
US20220009989A1 (en) 2022-01-13
AR116605A1 (es) 2021-05-26
EP3861017A1 (en) 2021-08-11
MA53809A (fr) 2022-01-12
CN112789289A (zh) 2021-05-11

Similar Documents

Publication Publication Date Title
JP7434299B2 (ja) インスリンペプチドおよびｅｇｆ（ａ）ペプチドを含む二官能性化合物
US11117947B2 (en) Double-acylated GLP-1 derivatives
JP6121992B2 (ja) ポリペプチド
JP6069198B2 (ja) Ｎ末端が修飾されたｆｇｆ２１化合物
US10093713B2 (en) GIP-GLP-1 dual agonist compounds and methods
US9012398B2 (en) Acylated exendin-4 compounds
JP6179864B2 (ja) グルカゴン／ｇｌｐ−１レセプタコ−アゴニスト
CN103200966B (zh) 具有接头的双-酰化的glp-1衍生物
JP6121330B2 (ja) 作用持続時間が増した改変ポリペプチド
JP6227629B2 (ja) ヒトアミリン類似体
US20240025957A1 (en) Insulin Derivative
CN103596583B (zh) 新型胰高血糖素类似物
KR20110040760A (ko) 대사 질환 및 비만 치료용 ｇｉｐ-기초된 혼합형 항진제
CN102933598A (zh) 新型胰高血糖素类似物
US20140303083A1 (en) GLP-1 Derivatives
JP2013518115A (ja) 代謝疾患及び肥満の治療のためのグルカゴンアンタゴニスト‐ｇｉｐアゴニスト複合体及び組成物
KR20170075779A (ko) Gip 효능제 화합물 및 방법
JP2014527975A (ja) 新規のグルカゴン類似体
KR20210005674A (ko) 글루카곤-유사 펩티드 1(glp-1) 융합 펩티드 커플링된 사이클릭 펩티드 티로신 티로신 접합체 및 이의 용도
KR101399178B1 (ko) 선별가능한 특성을 갖는 하이브리드 폴리펩티드
CN104968674A (zh) 具有胆固醇流出活性的新颖的glp-1受体激动剂
JP2015513544A (ja) Ｇｌｐ−１プロドラッグ
KR20200037793A (ko) 이기능성 화합물
CA2988841C (en) Protease-resistant lipidated glp-1 analogs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221003

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231117

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240207

R150 Certificate of patent or registration of utility model

Ref document number: 7434299

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150